CTNM earnings date and last-quarter result: last quarter beat, P/E -7.55. Updated 2026-07-23.
Contineum Therapeutics (CTNM) Research Hub
Contineum Therapeutics (CTNM) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 8.14 USD (-2.05%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -7.55, market cap 0.55B. This hub links to the full technical, earnings and options research available for CTNM.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 8.14 USD (-2.05%) |
| 52-week range | 6.73 USD – 17.79 USD |
| Trend regime | Range |
| 14-day RSI | 24.4 (Oversold) |
| Trailing P/E | -7.55 |
| Market cap | 0.55B |
| Dividend yield | 0.00% |
Available research for CTNM
Covered Call on CTNM: how it works, illustrative setup around the real 8.14 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CTNM: how it works, illustrative setup around the real 8.14 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CTNM: how it works, illustrative setup around the real 8.14 USD price, max profit/loss, breakeven and when to use it. Educational.
CTNM technical analysis: range, last 8.14 USD, RSI 24.4, 52w range 6.73 USD–17.79 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CTNM in?
Contineum Therapeutics (CTNM) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CTNM in an uptrend or downtrend?
As of 2026-10-26, CTNM is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CTNM's trailing P/E ratio?
CTNM's trailing P/E is -7.55, with a market cap of 0.55B. See the earnings research page for full valuation detail.